Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon to Sell Calif. CLIA Lab to Gain 'Efficiencies,' Free Up Resources

Premium

Exiqon announced that it will divest its California-based clinical laboratory improvement amendments-certified lab Oncotech to trim costs.

In late 2007, Exiqon announced it was acquiring Oncotech, a provider of molecular oncology testing services, for $45 million as part of an effort to build up its infrastructure and expertise to begin selling microRNA-based diagnostics (see RNAi News, 11/29/2007).

"Since the acquisition, Exiqon has successfully strengthened its product portfolio for in vitro diagnostics by adding new molecular tests … and other tools to help physicians improve cancer treatment selection," the company said this week. "Exiqon has now decided to consolidate its ongoing development of diagnostic products based on miRNA at the company's facilities in Denmark in order to gain operational and infrastructural efficiencies and to free up human and financial resources."

"This decision will help us focus on our core competencies in the area of miRNA and drive operational synergies between our two business areas, diagnostics and life sciences," Exiqon President and CEO Lars Kongsbak added in a statement.

The company said that as a result of the planned divestiture, it will seek partners to co-develop and commercialize its miRNA-based diagnostics.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.